A Cochrane review included 24 trials involving a total of 4 418 women. Triple-negative breast cancer (TNBC) is characterised by a lack of expression of oestrogen and progesterone receptors and human epidermal receptor 2 (HER2) and is assosiated with a shorter survival and higher likelihood of recurrence. In metatastatic TNBC platinum-containg regimens increased overall and progression-free survival compared with no platinum-containing regimens . In women with no TNBC, there was no response: the hazard ratio (HR) for overall survival was 1.01 (95% CI 0.92–1.12) and time to progression (overall HR 0.92; 95% CI 0.84–1.01). Adverse effects like leukopenia, hair loss, nausea and vomiting and anaemia were statistically significantly more common with platinum-containing regimens.
| Outcome | Hazard ratio (95% CI) | Risk with control - non-platinum chemotherapy | Risk with intervention - Platinum chemotherapy (95% CI) | No of participants (studies) Quality of evidence |
|---|---|---|---|---|
| Overall survival: 1-year risk of death | HR 0.75 (0.57 to 1.00) | 485 per 1000 | 392 per 1000 (315 to 485) | 391 (3) Low |
| Overall survival: 2-year risk of death | 655 per 1000 | 550 per 1000 (455 to 655) | ||
| Progression -free survival: 1-year risk of death | HR 0.59 (0.49 to 0.72) | 894 per 1000 | 733 per 1000 (667 to 801) | 391 (3) Low |
| Progression -free survival: 2-year risk of death | 987 per 1000 | 922 per 1000 (879 to 955) | ||
| Objective tumour response rate | RR 1.33 (1.13 to 1.56) | 354 per 1000 | 470 per 1000 (400 to 552) | 878 (5) Low |